VRS Verisante Technology Inc

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE
SERVICES.


Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF) (the "Company" or
"Verisante"), a leader in cancer detection technology, announced today that the
Company intends to complete two separate and independent brokered private
placements through Raymond James Ltd. (agent for sales in Canada only) and a
separate Agent for sales in the US (the "Agents"). The private placement to be
conducted by Raymond James Ltd. shall be for a minimum of 4,000,000 to a maximum
of 10,000,000 units at $0.50 per unit for total gross proceeds of a minimum of
$2,000,000 and a maximum of $5,000,000, and the private placement to be
conducted by the Company's US Agent shall be for a minimum of 4,000,000 to a
maximum of 10,000,000 units at $0.50 per unit for total gross proceeds of a
minimum of $2,000,000 and a maximum of $5,000,000, (collectively, the
"Offerings").


Each unit will comprise of one common share and one common share purchase
warrant (the "Warrants"). Each Warrant will entitle the holder to purchase one
common share at a price of $0.70 per share with an expiry date of 24 months from
the closing of the Offerings. 


The Warrants shall have two call provisions whereby in the event the volume
weighted average trading price of Verisante's common shares on the TSX Venture
Exchange (the "Exchange") is equal to or greater than $1.00 for 10 consecutive
trading days, the Company will have the right to accelerate the expiry date of
50% of the total Warrants issued under the Offerings to a date that is 30 days
after Verisante issues a news release announcing that it has elected to exercise
this acceleration right. Under the second call provision, in the event the
volume weighted average trading price of Verisante's common shares on the
Exchange is equal to or greater than $1.25 for 10 consecutive trading days, the
company will have the right to accelerate the expiry date of remaining 50% of
the total Warrants issued under the Offerings to a date that is 30 days after
Verisante issues a news release announcing that it has elected to exercise this
acceleration right.


Closing of the Offerings are scheduled to occur on or before April 30, 2013 or
at any other such time as the Company and each Agent may agree, subject to the
approval of the Exchange, the Agents' satisfactory due diligence, and other
customary conditions. The securities to be issued in connection with the
Offerings will be subject to a four month statutory hold period. 


These securities being offered have not been, and will not be, registered under
the United States Securities Act of 1933, as amended (the "U.S. Securities Act")
and may not be offered or sold in the United States or to, or for the benefit
of, U.S. persons (as defined in Regulation S under the U.S. Securities Act)
absent U.S. registration or an applicable exemption from the U.S. registration
requirements. This release does not constitute an offer for sale of securities
in the United States.


The net proceeds of the Offerings will be used to fund the Company's
manufacturing of Aura(TM), to pursue additional regulatory approvals of Aura(TM)
in the United States and other regions, to support sales and marketing
initiatives, and for working capital requirements. Commissions may be paid in
connection with the Offerings consisting of 10% of the gross proceeds of the
Offerings, and agent's warrants entitling the holder thereof to acquire common
shares of Verisante in an amount equal to 10% of the number of units sold by the
Agents, which agent's warrants shall have the same terms as the Warrants. 


About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative
systems for the early detection of cancer. The Verisante Aura(TM) for skin
cancer detection and the Verisante Core(TM) series for lung, colon and cervical
cancer detection utilize a proprietary cancer detection platform while the
operating software and probe technology are unique to each device. The cancer
detection platform was developed by the BC Cancer Agency and tested and refined
at the Skin Care Centre at Vancouver General Hospital. This exclusive platform
technology allows Verisante to develop and offer a range of compact,
non-invasive cancer detection devices that offer physicians immediate results
for many of the most common cancers. Aura(TM) has been approved for sale in
Canada, Europe and Australia. The Core(TM) has not yet been approved for sale. 


Verisante Aura(TM) was awarded Popular Science Magazine's "Best of What's New
Award" for 2011, and awarded a 2013 Prism Award for Innovation in Photonics.
Verisante Core(TM) was named one of the top 10 cancer breakthroughs of 2011 by
the Canadian Cancer Society. 


Youtube: www.youtube.com/verisante

Twitter: www.twitter.com/verisante

Facebook: www.facebook.com/verisante

Forward-Looking Statements 

This release contains forward-looking statements, including, but not limited to,
statements regarding the future commercialization of medical devices, the market
demand for these products and the proprietary protections the Company will
obtain with regard to the technology, all of which statements are subject to
market risks, and the possibility that the Company will not be able to obtain
patent protection or obtain sufficient customer demand. These statements are
made based upon current expectations and actual results may differ from those
projected due to a number of risks and uncertainties.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Verisante Technology, Inc.
Thomas Braun
President & CEO
(604) 605-0507
info@verisante.com
www.verisante.com

Verisante Technology (TSXV:VRS)
Historical Stock Chart
From Dec 2024 to Jan 2025

Verisante Technology (TSXV:VRS)
Historical Stock Chart
From Jan 2024 to Jan 2025